AstraZeneca Plans $200-Million Manufacturing Plant in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca Plans $200-Million Manufacturing Plant in China


ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca is investing $200 million in a new manufacturing site in China Medical City (CMC), Taizhou, Jiangsu province, China. The new site represents AstraZeneca’s largest investment in a single manufacturing facility globally.

The site will produce intravenous and oral solid medicines for the company’s business in China. Construction of the site is scheduled to be complete at the end of 2013.

AstraZeneca first established a presence in China in 1993 and generated more than $1 billion in revenues in that country in 2010. AstraZeneca’s other facilities and project work in China include a manufacturing and supply site in Wuxi New District, Jiangsu Province; the AstraZeneca Innovation Center China, a translational science center; an established sales and marketing operation; large-scale clinical development capabilities; and a network of collaborations with academic and medical institutions.

AstraZeneca’s plans for its new manufacturing site in China follow recent investment in emerging markets. In June 2011, AstraZeneca unveiled plans to establish a Predictive Science Center in St. Petersburg, Russia. The center will be staffed with 30 employees and focus on developing bioinformatics, data-analysis methods, software, and systems to help predict the safety and efficacy of potential new medicines. Earlier this year, the company began constructing a $150-million manufacturing facility in the Kaluga region to supply locally manufactured medicines in Russia.


See related Pharm Tech articles:

Big Pharma’s Manufacturing Blueprint for the Future (Pharm Tech)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here